Do you have the same question? Follow this Question
May 22, 2025 - 09:48 AM
We’ve provided several answers to questions related to Atelvia (Risedronate) Delayed Release , see some other helpful Q&A related to this product.
Question: What is the KEGG ID for this medication?
Answer: The KEGG ID is D08456. The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a resource for understanding high-level functions of the biological system, which can be beneficial in the context of drug interactions and pathways.
Question: What are some serious side effects of this medication?
Answer: Serious side effects can include esophageal irritation, low calcium levels, severe bone or joint pain, and unusual thigh bone fractures. Awareness of these risks ensures users can take action promptly to mitigate adverse outcomes.
Question: How should this medication be administered?
Answer: This medication should be taken orally as a delayed-release tablet. Proper administration is critical to ensure maximum absorption and effectiveness, while reducing potential side effects like esophageal irritation.
Question: What is the dosage strength of this medication?
Answer: The dosage strength of the delayed-release tablet is 35 mg. This specific dosage is designed to balance efficacy with safety, minimizing the risk of side effects while ensuring therapeutic benefits.
Question: What is the formula of the active ingredient in this medication?
Answer: The formula for Risedronate Sodium, the active ingredient, is C7H10NO7P2Na. This formula is crucial for understanding the chemical composition of the medication, which helps in ensuring its efficacy and safety in treating osteoporosis.
View all Atelvia (Risedronate) Delayed Release Questions & Answers
